A PHASE I/II STUDY OF NERATINIB IN PEDIATRIC PATIENTS WITH RELAPSED/ REFRACTORY SOLID TUMORS

Registry ID

POE16-01

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

PEDIATRIC ONCOLOGY EXPERIMENTAL THERAPEUTIC INVESTIGATOR CONSORTIUM

Start date

2017-11-20

Last update

2017-07-06

Conditions

• HEMATOLOGICAL MALIGNANCIES
• RELAPSED OR REFRACTORY SOLID TUMORS

Related clinical trials

• A PHASE I STUDY OF GCAR1, A CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY FOR PARTICIPANTS WITH SELECTED RELAPSED/REFRACTORY GPNMB-EXPRESSING SOLID TUMOURS
• PHASE I/II STUDY OF SILMITASERTIB (CX-4945) IN COMBINATION WITH CHEMOTHERAPY IN CHILDREN AND YOUNG ADULTS WITH RELAPSED REFRACTORY SOLID TUMORS
• LIGHTBEAM-U01 SUBSTUDY 01A: A PHASE 1/2 SUBSTUDY TO EVALUATE THE SAFETY AND EFFICACY OF ZILOVERTAMAB VEDOTIN IN PEDIATRIC AND YOUNG ADULT PARTICIPANTS WITH HEMATOLOGIC MALIGNANCIES OR SOLID TUMORS
• A PHASE I-II, FIRST-IN-HUMAN STUDY OF SKB264 IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE /METASTATIC SOLID TUMORS WHO ARE REFRACTORY TO AVAILABLE STANDARD THERAPIES.
• AN OPEN-LABEL, MULTICENTER, ROLL-OVER STUDY FOR PATIENTS WHO HAVE COMPLETED A PRIOR NOVARTIS-SPONSORED SABATOLIMAB (MBG453) STUDY AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED TREATMENT WITH SABATOLIMAB
• PHASE 1/2 STUDY OF 9-ING-41, A GLYCOGEN SYNTHASE KINASE-3 BETA (GSK-3B) INHIBITOR, AS A SINGLE AGENT AND COMBINED WITH CHEMOTHERAPY, IN PATIENTS WITH REFRACTORY HEMATOLOGIC MALIGNANCIES OR SOLID TUMORS

View on source registry